Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Trinity Universal Research Associates Inc

Neither a doctor nor a teaching hospital

Research payments

$677,722

190 payments

Through program year 2025, Trinity Universal Research Associates Inc is reported as receiving $677,722 in research payments, across 190 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $34,026 5
2024 Research $7,414 2
2023 Research $28,760 11
2022 Research $41,844 28
2021 Research $109,255 34
2020 Research $182,037 49
2019 Research $274,386 61

Breakdown

Who paid Research payments · program years 2019–2025
  1. Gilead Sciences, Inc. $414,402 86 payments
  2. Pfizer Inc. $88,830 40 payments
  3. GlaxoSmithKline, LLC. $62,626 33 payments
  4. Hexal AG $37,886 9 payments
  5. Eli Lilly and Company $20,700 1 payment
  6. Dr.Reddy's Laboratories,Inc. $18,110 9 payments
  7. Otsuka Pharmaceutical Development & Commercialization, Inc. $12,700 2 payments
  8. Allergan Inc. $10,763 5 payments
  9. Novartis Pharmaceuticals Corporation $6,029 1 payment
  10. E.R. Squibb & Sons, L.L.C. $4,714 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Phase 3B4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to A Tumor Necrosis Factor TNF Inhibitor in Subjects With Rheumatoid Arthritis $76,154 38 payments
  2. Cgp24112301 $37,886 9 payments
  3. A Multi-Centre Long-Term Extension Study to Assess the Safety and Effi $34,083 27 payments
  4. Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Psa) $20,700 1 payment
  5. A Phase 3 randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continued Treatment With Rituxan or MabThera $18,110 9 payments
  6. A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An $15,486 4 payments
  7. A Randomized, Placebo-controlled, Multicenter, Double-blind, Phase 2 Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects with Active Sjogren's Syndrome $15,455 1 payment
  8. A Randomized, Placebo-controlled, Multicenter, Double-blind, Phase 2 Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects with Active Sjogren's Syndrome $13,734 1 payment
  9. A Phase 4, Multicenter, Prospective, Open-Label Study Describing the E $13,057 2 payments
  10. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deuterated [D6]-Dextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimers Type $12,700 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record